Sleep apnea, a sleep disorder treated with medical devices, now has its first FDA-approved drug therapy, Zepbound, by Eli Lilly. The drug, initially developed for metabolic conditions, is an injectable medication used in combination with a reduced-calorie diet and exercise. Zepbound activates GLP-1 and GIP receptors to regulate blood sugar, reduce appetite, and aid in weight loss, helping to improve sleep apnea. Clinical studies showed a significant reduction in breathing disruptions and weight loss with Zepbound. This approval presents a competitive challenge to CPAP device makers. Lilly is exploring additional applications for Zepbound, such as fatty liver disease and cardiovascular indications.
Source link
Eli Lilly’s Zepbound Becomes First FDA-Approved Drug Therapy for Sleep Apnea
